Harvard Bioscience Q3 Revenue Up 8% to $22.2M; Full-Year EBITDA Guidance Cut
HBIO has more than doubled off its 52-week low of $4 on elevated volume (2.3× avg).
Summary
Harvard Bioscience grew Q3 revenue 8% to $22.2M but gross margin compressed to 55.4% and full-year adjusted EBITDA guidance was cut to (1%)-4% growth. The net loss widened to $2.6M and cash fell to $4.9M against $37.2M of debt.
Key Events · Earnings and Guidance · HBIO
-
Q3 Revenue Grows 8% to $22.2M
Third-quarter 2026 revenue was $22.2 million versus $20.6 million a year earlier, with double-digit growth to CROs and China customers in organoids, respiratory and fluidics products.
-
Gross Margin Compresses to 55.4%
GAAP gross margin fell from 58.4% to 55.4% and adjusted gross margin from 59.2% to 57.1%, driven by higher sales of lower-margin CMT products and greater distribution and China contribution.
-
Full-Year EBITDA Guidance Cut
Full-year 2026 adjusted EBITDA is now expected at (1%) to 4% growth, while revenue growth guidance of 3%-5% and adjusted gross margin of 57%-59% were reaffirmed.
-
Net Loss Widens, Cash Burn Returns
Q3 net loss was $2.6 million versus $1.2 million a year ago; interest expense rose to $1.8 million from $1.3 million and operating cash flow was $(0.2) million versus $1.0 million.
Analysis · HBIO · Industrial Applications And Services
Revenue growth is real — $22.2M in Q3 versus $20.6M a year ago — but the quality of that growth is deteriorating. Gross margin fell to 55.4% from 58.4% as lower-margin CMT products and distribution/China sales took a bigger share of the mix, and the company now expects full-year adjusted EBITDA of (1%) to 4% growth instead of prior expectations. Net loss widened to $2.6M from $1.2M, interest expense rose to $1.8M from $1.3M, and operations burned $0.2M of cash in the quarter versus generating $1.0M a year ago. With $4.9M of cash against $37.2M of debt, the reaffirmed revenue guide matters less than the margin and cash trajectory.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HBIO was trading at $9.09 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $41.4M. The 52-week trading range was $4.00 to $9.32. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.